Clinical Trial Update: Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on a chemotherapy-immunotherapy-based split-course adaptive hypofractionated radiotherapy for extensive-stage small-cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Small-cell Lung Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION